South Korea
· Delayed Price · Currency is KRW NGeneBio Statistics
Total Valuation
NGeneBio has a market cap or net worth of KRW 40.92 billion. The enterprise value is 49.85 billion.
| Market Cap | 40.92B |
| Enterprise Value | 49.85B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NGeneBio has 12.89 million shares outstanding. The number of shares has increased by 2.29% in one year.
| Shares Outstanding | 12.89M |
| Shares Change (YoY) | +2.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.75% |
| Owned by Institutions (%) | 1.05% |
| Float | 9.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.17 |
| PB Ratio | 3.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.75 |
| EV / Sales | 9.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.28 |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of 1.02.
| Current Ratio | 0.52 |
| Quick Ratio | 0.39 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.11 |
| Interest Coverage | -7.67 |
Financial Efficiency
Return on equity (ROE) is -84.20% and return on invested capital (ROIC) is -29.48%.
| Return on Equity (ROE) | -84.20% |
| Return on Assets (ROA) | -20.66% |
| Return on Capital (ROIC) | -29.48% |
| Revenue Per Employee | 48.91M |
| Profits Per Employee | -130.24M |
| Employee Count | 102 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.44% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -49.44% |
| 50-Day Moving Average | 3,048.40 |
| 200-Day Moving Average | 4,057.70 |
| Relative Strength Index (RSI) | 48.73 |
| Average Volume (20 Days) | 2,090,189 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NGeneBio had revenue of KRW 4.99 billion and -13.28 billion in losses. Loss per share was -1,035.69.
| Revenue | 4.99B |
| Gross Profit | 1.97B |
| Operating Income | -13.55B |
| Pretax Income | -14.14B |
| Net Income | -13.28B |
| EBITDA | -11.80B |
| EBIT | -13.55B |
| Loss Per Share | -1,035.69 |
Balance Sheet
The company has 5.47 billion in cash and 12.90 billion in debt, giving a net cash position of -7.43 billion or -576.25 per share.
| Cash & Cash Equivalents | 5.47B |
| Total Debt | 12.90B |
| Net Cash | -7.43B |
| Net Cash Per Share | -576.25 |
| Equity (Book Value) | 12.61B |
| Book Value Per Share | 862.27 |
| Working Capital | -8.74B |
Cash Flow
In the last 12 months, operating cash flow was -10.87 billion and capital expenditures -768.67 million, giving a free cash flow of -11.64 billion.
| Operating Cash Flow | -10.87B |
| Capital Expenditures | -768.67M |
| Free Cash Flow | -11.64B |
| FCF Per Share | -902.85 |
Margins
Gross margin is 39.56%, with operating and profit margins of -271.64% and -266.29%.
| Gross Margin | 39.56% |
| Operating Margin | -271.64% |
| Pretax Margin | -283.53% |
| Profit Margin | -266.29% |
| EBITDA Margin | -236.45% |
| EBIT Margin | -271.64% |
| FCF Margin | -233.27% |
Dividends & Yields
NGeneBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.29% |
| Shareholder Yield | -2.29% |
| Earnings Yield | -32.62% |
| FCF Yield | -28.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NGeneBio has an Altman Z-Score of -1.99. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.99 |
| Piotroski F-Score | n/a |